In animal models bearing tumors, FMT using microbiota from donors who responded positively to ICI treatment was shown to boost the anti-tumor activity of anti-PD-(L)1 agents and strengthen T cell-driven anti-tumor responses. The gene discussed is CD274; the disease is neoplasm.